Session 2G: The Association of High Lipid Levels and Muscle Inflammation in Juvenile Dermatomyositis
Session Number
Session 2G: 1st Presentation
Advisor(s)
Lauren Pachman, Ann & Robert H. Lurie Children's Hospital of Chicago
Location
Room A117
Start Date
28-4-2017 10:00 AM
End Date
28-4-2017 11:15 AM
Abstract
Juvenile dermatomyositis (JDM) is an autoimmune disease that affects children with muscle inflammation, weakness, and skin rashes. The main way to treat JDM is using corticosteroids and to track the progression of the disease, the disease activity score (DAS) can be used. In a typical JDM patient, the lipid levels are higher than in a normal, healthy child. The association between the high lipid levels and JDM can be due to inflammation in muscles or due to the medications. In the study, data was queried from the pediatric rheumatology clinic to form four treatment status groups; untreated patients, patients with a low DAS on medication, patients with a high DAS on medication, and patients that had completed treatment. From the lipid panel data given for each patient, four main lipids were used in the study; cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides. Data for selected patients were sent to a biostatistician for statistical conclusions. Preliminary results indicate that the high lipid levels do not relate directly to muscle inflammation. Still, further studies are necessary to determine if the lipid levels can be due to chronic inflammation or therapy involved with JDM.
Session 2G: The Association of High Lipid Levels and Muscle Inflammation in Juvenile Dermatomyositis
Room A117
Juvenile dermatomyositis (JDM) is an autoimmune disease that affects children with muscle inflammation, weakness, and skin rashes. The main way to treat JDM is using corticosteroids and to track the progression of the disease, the disease activity score (DAS) can be used. In a typical JDM patient, the lipid levels are higher than in a normal, healthy child. The association between the high lipid levels and JDM can be due to inflammation in muscles or due to the medications. In the study, data was queried from the pediatric rheumatology clinic to form four treatment status groups; untreated patients, patients with a low DAS on medication, patients with a high DAS on medication, and patients that had completed treatment. From the lipid panel data given for each patient, four main lipids were used in the study; cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides. Data for selected patients were sent to a biostatistician for statistical conclusions. Preliminary results indicate that the high lipid levels do not relate directly to muscle inflammation. Still, further studies are necessary to determine if the lipid levels can be due to chronic inflammation or therapy involved with JDM.
Comments
Additional team members: Gabrielle Morgan